William Blair Reiterates Outperform On Exact Sciences Following Discussion With Management
In a research note released Wednesday, William Blair analyst Brian Weinstein reiterated coverage on Exact Sciences Corporation (EXAS) with a Buy rating, after he spent the day at Exact Sciences’ headquarters in Madison, Wisconsin, and came away with two key conclusions as follow:
- First, we are confident that if Cologuard is granted FDA approval, the company will be extremely well prepared to successfully launch the test from an operational standpoint. The company’s facilities, which now include a fully operational lab and state-of-the-art call center, are very impressive and the team that CEO Kevin Conroy has built seems extremely capable of commercializing this test.
- Second, management remains confident that the pathway to securing favorable reimbursement is clear”.
No price target was assigned.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Brian Weinstein currently has a one-year average return of 38.5% and a 100% success rate. Weinstein is ranked #1092 out of 3155 analysts.